Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Wall Street Zen to “Sell” Rating

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

IKT has been the topic of a number of other reports. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Monday, December 1st. Zacks Research upgraded shares of Inhibikase Therapeutics to a “hold” rating in a report on Tuesday, December 2nd. Cantor Fitzgerald upgraded Inhibikase Therapeutics to a “strong-buy” rating in a research note on Thursday, December 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Inhibikase Therapeutics Trading Up 21.2%

Shares of IKT opened at $2.00 on Friday. The firm has a market cap of $150.36 million, a price-to-earnings ratio of -5.13 and a beta of 0.88. The business’s fifty day simple moving average is $1.56. Inhibikase Therapeutics has a 12 month low of $1.33 and a 12 month high of $3.49.

Inhibikase Therapeutics (NASDAQ:IKT) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.